Search PubMed⌕ Search

Biomedical subjects

M Tehrani

Publications and source records attributed to M Tehrani.

7 recordsLinked to original sources
PubMed2002

[Complications with foldable intraocular lenses with subsequent explantation in 1998 and 1999. Results of a questionnaire evaluation].

PURPOSE: A questionnaire was sent to all members of the German Society of Ophthalmic Surgeons to evaluate complications of foldable intraocular lenses (IOLs) that required explanation. METHODS: Information on preoperative visual acuity, foldable IOL design and material as well as the reason for IOL explantation was obtained and analysed. We received 167 completed questionnaires for 1998 and 1999. RESULTS: In 1998 and 1999 the most common reasons for IOL explantation were as follows: incorrect lens power for 56% of the 3-piece hydrophobic acrylic IOLs, 16% because of glare or other photic phenomena, 40% of the 1-piece hydrophilic acrylic IOLs were explanted because of incorrect lens power and 30% for IOL damage. For the 3-piece monofocal silicone IOLs, 41% were explanted because of incorrect IOL power and 32% because of IOL decentration. For the 1-piece Hydrogel IOL, 76% were explanted because of opacification of the optic and 14% because of incorrect lens power. Most multifocal IOLs were explanted because of photic phenomena. CONCLUSION: In addition to the most common complications such as decentration and incorrect IOL power observed in rigid IOLs, new complications associated with foldable IOLs occurred such as optic opacification, glare and photic phenomena. Some complications seemed to appear in particular IOL types (opacification: SC-60BOUV, MDR), while others were observed in all types of foldable lenses. Accurate calculation of the IOL power and further improvement of the IOL material and design seem to be necessary to minimise the rate of explantations.

Device Removal↗
PubMed2002

[Striae in the flap after laser in situ keratomileusis. Etiology, diagnosis and treatment].

OBJECTIVE: Laser in situ keratomileusis (LASIK) has become the leading refractive option to correct myopia, hyperopia and astigmatism. In addition to the relative rapid visual recovery and the lack of postoperative pain, new flap-related complications are being added. The formation of striae can lead to a significant loss of corrected visual acuity if the central pupil zone is affected. Awareness of possible complications is important not only for the surgeon, but also for the ophthalmologist in practice for a rapid diagnosis and prompt management. CLINICAL COURSE AND THERAPY: Striae have a variety of appearances and are caused by misalignment/displacement of the corneal flap after replacement or are results of a slippage effect of the flap over the stromal bed after LASIK. Symptomatic striae ideally are treated on the first or second day after surgery by refloating the flap, irrigation with balanced salt solution or hypotonic saline solution, stroking and stretching the surface with moist and dry sponges. In more severe cases scraping away the epithelium and antitorque or interrupted sutures can be performed to treat persistent striae. CONCLUSION: Symptomatic deep striae should be diagnosed early and managed promptly within the first days. Any later intervention decreases the chance of successful elimination and visual outcome. Hints to prevent the development of striae formation are provided.

Corneal Diseases↗
PubMed2001

[Toric intraocular lens to correct high astigmatism after penetrating keratoplasty in a pseudophakic eye - a case report].

BACKGROUND: After penetrating keratoplasty residual astigmatism can be treated with various options. Correction with spectacles or contact lenses, methods such as radial keratotomy, photorefractive keratectomy (PRK) or Laser-in-situ keratomileusis (LASIK) are limited only to mild and moderate astigmatism. In laser ablation a sufficient corneal thickness must be ensured. On the other hand surgical correction is performed on transplanted tissue which can increase the risk of allograft rejection. In pseudophakic eyes the implantation of an individually designed toric intraocular lens (IOL) according to keratometry and biometry with a cylindrical power up to 12 D provides an alternative method for correcting higher astigmatism. This individually designed IOL can be implanted additionally to the existing IOL. CASE: A 66-year-old patient presented after penetrating keratoplasty and implantation of an IOL 4 years ago with a visual acuity of 20/160 and residual astigmatism of - 10 D x 151(o). After biometry an individually manufactured toric PMMA-IOL of + 12 D cylindrical and - 9.5 D spherical power was implanted via a sclerocorneal tunnel incision additionally to the existing IOL into the ciliary sulcus. Postoperatively a well centered and stable positioned IOL was found. One year after implantation of the toric IOL the position was still unchanged and the graft had remained clear. Spherical equivalent refraction was + 1,5 D - 3,0 D x 141(o), with an uncorrected visual acuity of 20/60. CONCLUSION: Implantation of a toric intraocular lens in pseudophakic eyes allows the correction of high astigmatism after penetrating keratoplasty. The advantage of this method compared to the keratorefractive options lies in its minor manipulation on the allograft.

Aged↗
PubMed1998

[Not Available].

Explore the source record for details and available documents.

Attitude to Death↗
PubMed1989

Rational use of biological response modifiers in hematological malignancies--a review of treatment with interferon, cytotoxic cells and antibodies.

During the last decade the use of various biologic therapeutics/biological response modifiers in hematological malignancies has increased dramatically. Alpha-interferon (alpha-IFN) alone has clearly a substantial antitumoral effect in many hematological diseases. During the coming decade an improved effect will probably be seen by combination of alpha-IFN with cytostatics and other biologic therapeutics as well as by finding the optimal conditions when alpha-IFN should be used. Using unconjugated mouse monoclonal antibodies (MAb) only, an overall response rate of 38% was noted in patients with advanced disease. MAb therapy might be improved by using other Ig molecules, combination with cytokines and by finding an optimal dosage schedule. Only a few patients with hematological malignancies have been treated with IL-2/LAK cells. An overall response rate of 41% was seen in heavily pretreated patients. In all biologic therapeutics, an improved efficacy will be noted if patients with a low tumor burden and an intact immune system are treated. Immunization/vaccination with "tumor antigen" will probably contribute to an improved prognosis, especially in patients with minimal residual disease. There are several good candidates to be used as tumor antigens in hematological malignancies i.e. the idiotypic receptors on T and B cells. Biotherapy in hematological tumors has come to stay. However, due to the complexity of the effector system it will take a long time before an effective treatment concept is developed.

Antibodies, Monoclonal↗
PubMed1983

Endotoxaemia in septic shock: clinical and post mortem correlations.

The Limulus amoebocyte lysate assay was used as one of a series of laboratory and clinical investigations on a group of 31 patients suffering from septic shock in order to assess the clinical significance of this assay for the detection of circulating endotoxin in clinical gram-negative sepsis. Four patients with cardiogenic shock served as controls. Endotoxin was detected in the bloodstream of all patients with septic shock during the 24 h following referral and was not detected in the control patients. Eventual clinical recovery was associated with the disappearance of endotoxin from the peripheral blood. Blood cultures were unhelpful as a prognostic indicator in these critically ill patients. A quantitative assay of endotoxin in blood may allow a more precise relationship with the clinical manifestations of major sepsis.

Adolescent↗